US · Healthcare · Diagnostics & Research
EPS came in at 2.11 against a street estimate of 1.92 — a beat of 9.9%.
Analysts rate Danaher Corporation a strong buy (20 buy, 4 hold, 0 sell out of 24) with an average price target of $259.90.
CONFIDENT Danaher exceeded expectations, raised 2026 EPS guidance, and sees improving demand. Management is prioritizing commercial execution, innovation, talent, AI, and disciplined capital allocation. Q3 FY26 Developed-market revenue was flat overall, while high-growth markets increased approximately 10%; North America was pressured mainly by lower respiratory revenue. Analysts pressed management on the new CEO’s priorities, 2027 growth assumptions, respiratory weakness, AI, commercial execution, M&A, Masimo, and end-market recovery. Management emphasized stronger execution, disciplined investment, improving demand, and cautious respiratory assumptions. 2026-10-21…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 7.84% |
| Vanguard Capital Management, LLC | 5.89% |
| FMR Inc | 4.20% |
| State Street Corp | 4.05% |
| Wellington Management Company LLP | 2.32% |
| Capital Research & Mgmt Co - Division 3 | 2.21% |
| Geode Capital Management, LLC | 2.03% |
| Vanguard Portfolio Management, LLC | 2.02% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 sales were $6,554 million, up from $6,053 million in the comparable quarter. • Nine-month sales were $18,770 m | 2026-10-21 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Danaher reported third-quarter 2026 revenue of $6.6 billion, up 8.5% year over year. • Net earnings were $1.2 billion, or $1.71 p | 2026-10-21 |
| Board / officer change · Q4 2026 HEADLINE NUMBERS • Danaher increased its Board of Directors from 11 to 13 members on October 9, 2026. • Daniel L. Comas and Robert M. Hershberg, M.D | 2026-10-13 |
| Board / officer change · Q3 2026 DANAHER CORPORATION - 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Julie Sawyer Montgomery appointed as President and CEO effective October 1, 2026, | 2026-08-03 |
| Quarterly report · Q2 2026 DANAHER CORPORATION – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Six-month sales (ended June 26, 2026): $12,216 million vs. $11,677 million prior year | 2026-07-21 |
| Results announced · Q3 2026 DANAHER CORPORATION – Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Net earnings: $870 million, or $1.23 per diluted share, up 60% year-over-year • No | 2026-07-21 |
| Company announcement · Q2 2026 DANAHER CORPORATION - 8-K FILING SUMMARY HEADLINE NUMBERS • Total debt issuance: CHF 2,382,430,000 (~$2.6 billion USD equivalent) • Seven separate n | 2026-06-03 |
| Board / officer change · Q2 2026 DANAHER CORPORATION (DHR) - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held May 5, 2026 • Omnibus Incentive Plan approved with 2 | 2026-05-07 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.40 / share ex-date Sep 30, 2026 · pay Oct 30, 2026 | 2026-09-30 |
| Dividend | $0.40 / share ex-date Jun 26, 2026 · pay Jul 31, 2026 | 2026-06-26 |
| Dividend | $0.40 / share ex-date Mar 27, 2026 · pay Apr 24, 2026 | 2026-03-27 |
| Dividend | $0.32 / share ex-date Dec 26, 2025 · pay Jan 30, 2026 | 2025-12-26 |
| Announcement | Date |
|---|---|
| CEO to comment on 2025 financial performance at healthcare conference Danaher Corporation filed an 8-K on January 12, 2026, announcing that its CEO will comment on financial performance at the J.P. Morgan Healthcare Conference on January 13, 2026. The filing i | 2026-01-12 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Danaher Corporation — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.